ARTICLES BY KATE HAMMEKE

• Trends In Bioprocessing CDMO Selection

  Which CDMO characteristics do experienced outsourcers value the most when choosing a CDMO for biologic API production? Data from the past three iterations of ISR’s Bioprocessing Market Trends and Outsourcing Dynamics show the top selection metrics remain cosnsistent despite some shifts in ranks over the years. Learn which attributes to focus on as a sponsor or CDMO.

• Trends In Bioprocessing CDMO Selection

  Learn which CDMO characteristics experienced outsourcers value most from ISR’s Bioprocessing Market Trends and Outsourcing Dynamics report.

• Outsourcing Success Requires Constant Evolution

  Industry Standard Research explains how Life Science Leader’s CMO Leadership Awards and market research data can help biopharma companies make more informed CMO selection decisions.

• Sponsor Challenges When Outsourcing Sterile Injectables

  ISR asked outsourcers of sterile injectable drug product to identify their biggest challenge when outsourcing to CDMOs/CMOs. Here's a look at the resulting nearly four-way tie.

• The Top CROs By Therapeutic Indication Share Strong Regulatory And Productivity Performance

  A recent market research study revealed that 59 percent of sponsors place therapeutic experiences as the top attribute that influences CRO selection.  Nice Insight’s outsourcing survey indicated the most popular therapeutic areas of focus for outsourced projects were cardiovascular disease, oncology, and infectious disease.

• Outsourcing Motivations Should Guide One’s Outsourcing Approach

  Outsourcing motivations are important considerations to identify the best outsourcing approach and should influence the type of relationships your organization develops with CMOs. Data comes from ISR’s CMO Quality Benchmarking suite of market research reports and ISR’s Development and Commercial Outsourcing Models market research report.

• Areas Of Growth For Oral-Dose Outsourcing

  Data from ISR’s Oral Dosage Forms Market Overview and Outlook (3rd Edition) report covers growth in outsourced manufacturing and how that aligns with drug innovators’ life cycle extension strategies.

• Are Preferred Provider Agreements the Best Model For Outsourced Manufacturing?

  ISR has observed use of preferred provider agreements (PPAs) and the proportion of outsourcing allocated to preferred providers increase over the past three years.

• A Hypothetical Question About Outsourcing Services Leads To … More Questions?

  If you were in charge of establishing a bioprocessing contract manufacturing business, which service provider attributes would you ensure your company excelled at? Here's how your peers responded.

• Improving Outsourcing Relationships

  ISR's Development and Commercial Outsourcing Models report indicates that proactive communication between sponsors and CMOs in these three areas will help to improve outsourcing relationships.

• What Makes It So Hard To Select A CMO?

  Learn the unexpected findings from the Industry Standard Research Outsoucing Models survey, from the perspective of a market researcher.